论文部分内容阅读
目的:探讨口服磺脲类、二甲双胍联合胰岛素治疗控制不良的2型糖尿病应用罗格列酮的疗效。方法:将52例磺脲类、二甲双胍联合胰岛素治疗控制不良的2型糖尿病患者随机分为罗格列酮组和对照组。治疗12周后,观察两组的血糖控制、胰岛素用量、血脂、体重的变化。结果:治疗12周后,与对照组相比,罗格列酮组血糖控制良好,明显优于对照组(P<0.01),且胰岛素剂量减少21.7%,而对照组胰岛素剂量却增加了19.1%。罗格列酮组甘油三酯较前有明显下降(P<0.01),胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、体重与治疗前无明显变化(P>0.05)。结论:对于口服磺脲类、二甲双胍药联合胰岛素控制不良的2型糖尿病患者,加用罗格列酮能使血糖得到较好的控制,是一种有效安全的选择。
Objective: To investigate the efficacy of oral administration of rosuvastatin in type 2 diabetes mellitus treated with oral sulfonylureas and metformin combined with insulin. Methods: Fifty-two patients with type 2 diabetes who had poor control of sulfonylureas and metformin combined with insulin were randomly divided into rosiglitazone group and control group. After 12 weeks of treatment, the blood sugar control, insulin dosage, blood lipid and body weight of the two groups were observed. Results: Compared with the control group, the blood glucose of rosiglitazone control group was significantly better than that of the control group (P <0.01) after 12 weeks treatment, and the insulin dosage decreased by 21.7%, while the insulin dosage of the control group increased by 19.1% . Triglyceride triglyceride in rosiglitazone group decreased significantly (P <0.01), while cholesterol, HDL-C, LDL cholesterol and body weight did not change significantly before treatment (P> 0.05). CONCLUSIONS: Oral sulfonylureas and metformin combined with insulin-poor type 2 diabetes mellitus are more effective and safe for patients with type 2 diabetes who are better able to control blood sugar with rosiglitazone.